2026-04-14 13:49Revenue Growth - For the year ended December 31, 2025, total revenue was $5,343,033,000, a significant increase from $3,810,241,000 in 2024, representing a year-over-year growth of approximately 40.3%[13] Gross Profit Margin - The gross profit margin ratio for China was 66.6% in 2025, up from 62.9% in 2024, while the gross margin for Ex-China remained stable at 97.0% compared to 97.1% in 2024[13] - The Company’s gross profit margin ratio for the total revenue was not explicitly stated but can be inferred from the regional breakdown, indicating strong profitability across its operations[12] Research and Development Expenses - Total research and development expenses for 2025 amounted to $2,145,868,000, an increase from $1,953,295,000 in 2024, reflecting a year-over-year growth of approximately 9.8%[14] - R&D expenses for the pipeline product Sonrotoclax (BCL2 Inhibitor) were $176,716,000 in 2025, significantly higher than $99,939,000 in 2024, indicating a focus on this product's development[14] - The Company allocated $97,646,000 for R&D expenses on BRUKINSA (zanubrutinib, BTK inhibitor) in 2025, down from $129,226,000 in 2024, suggesting a strategic shift in resource allocation[14] - The total external R&D expenses reached $858,720,000 in 2025, compared to $728,660,000 in 2024, indicating an increase of approximately 17.8%[14] - The Company’s internal R&D expenses totaled $1,287,148,000 in 2025, slightly up from $1,224,635,000 in 2024, showing a continued investment in internal projects[14] Production and Inventory - The production quantity of key products for the year ended December 31, 2025, was 6,268,800 vials, with sales quantity reaching 5,996,100 vials, resulting in an inventory stock of 2,912,600 vials as of the same date[17] Strategic Moves - The Company transferred its royalty rights to an independent third party for a fixed upfront cash consideration in 2025, reflecting a strategic move in its collaborative drug development efforts[8]